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Summary 
The smaller form of the GABA-synthesizing enzyme glutamic acid decarboxylase (GADrs) is 
a major autoantigen i  two human diseases that affect its principal sites of expression. Thus, 
destruction ofpancreatic B cells, which results in insulin-dependent diabetes mellitus (IDDM), 
and impairment of GABA-ergic synaptic transmission i Stiff-Man syndrome (SMS) are both 
characterized bycirculating autoantibodies to GADrs. Anti-GADrs autoantibodies in IDDM are 
predominantly directed to conformational epitopes. Here we report he characterization of humoral 
autoimmune r sponses to GAD6s in 35 SMS patients, of whom 13 (37%) also had IDDM. All 
SMS patients immunoprecipitated native GAD6s and the main titers were orders of magnitude 
higher than in IDDM patients. Furthermore, incontrast to the situation in IDDM, autoantibodies 
in 35 of 35 (100%) of SMS patients recognized enatured GADrs on Western blots. Two major 
patterns of epitope specificity were identified on Western blots. The first pattern, detected in
25 of 35 SMS patients (71%), of whom 11 had IDDM (44%), was predominantly reactive with 
a linear NH2-terminal epitope residing in the first eight amino acids of GADrs. Nine of nine 
individuals who were HLA-haplotyped in this group carried an IDDM susceptibility haplotype 
and HLA-DR3, DQw2 was particularly abundant. The second pattern, detected in 10 of 35 
patients (29%) of whom two had IDDM (20%), included reactivity with the NH2-terminal 
epitope plus strong reactivity with one or more additional epitope(s) residing COOH-terminal 
to amino acid 101. The second epitope pattern may represent epitope spreading in the GAD6s 
molecule, but may also include some cases of epitope recognition associated with IDDM resistant 
HLA-haplotypes. The principal NH2-terminal inear epitope in GADrs distinguishes the 
reactivity of SMS and IDDM autoantibodies and may be a determinant of pathogenicity for 
GABA-ergic neurons. The greater magnitude and distinct specificity of the humoral response 
to GAD6s in SMS may reflect a biased involvement of the T helper cell type 2 (Th2) subset 
of CD4 + T cells and antibody responses, whereas IDDM is likely mediated by the Thl subset 
of CD4 + T cells and cytotoxic T cell responses. 
T he synthesizing enzyme for the inhibitory neurotrans- mitter GABA, glutamic acid decarboxylase (GAD) 1, is 
encoded by two nonallelic genes, GAD6s and GAD67 (1), 
which share a similar exon-intron structure and are probably 
t Abbreviations u ed in this patx, r:AET, aminoethylisothiouranium bro ide; 
DTT, dithiothreitol; F/M, female/male; GAD, glutamic acid decarboxylase; 
derived from a common ancestral gene (2). These two GAD 
proteins share xtensive homology except in their first 95 amino 
HMAP, Hepes/NaOH/MgC12, AET, PLP; ICA, islet cell cytoplasmic 
antibodies; IDDM, insulin-dependent diabetes mellitus; JDF; Juvenile 
Diabetes Foundation; PLP, pyridoxal 5'phosphate; PVDF, polyvinylidene 
difluoride; SMS, Stiff-Man syndrome; TBS, tfis-buffered saline. 
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acids (1). Both are synthesized as hydrophilic soluble mole- 
cules (3), but only GAD6s, which is found in neurons and 
pancreatic/3 cells, undergoes posttranslational lipid modifica- 
tion in the NH2-terminal domain to become targeted and 
anchored to the membrane of synaptic-like microvesicles, 
which store and secrete GABA (3-5). 
Autoantibodies to GAD6s are detected in ~80% of indi- 
viduals who develop insulin-dependent diabetes mellitus 
(IDDM) (6, 7). Autoantibodies to GADs7 are detected in 
only a small fraction of IDDM patients, and seem to repre- 
sent anti-GAD6s autoantibodies that crossreact with the 
larger isoform (8, 9). T lymphocytes are implicated as the 
effectors of B cell destruction (10). GAD6s has been iden- 
tified as the primary T cell autoantigen i the nonobese dia- 
betic mouse model of IDDM, and induction of tolerance to 
GAD6s in young mice prevents the disease (11, 12). 
Autoantibodies to GAD65 are also found in a rare neuro- 
logical disorder called Stiff-Man syndrome (SMS) (13). Stiffness 
of axial muscles and superimposed painful spasms are charac- 
teristic of this disorder and are alleviated by beuzodiazepines, 
a finding that is consistent with the hypothesis that SMS 
represents an impairment of GABA-ergic neurotransmission 
in the central nervous ystem (14). SMS is characterized by 
a 30-40% coincidence with IDDM. Conversely, however, 
SMS is diagnosed in ~1/104 IDDM patients and in ~1/106 
individuals in the general population. If GAD is a primary 
autoantigen i  both SMS and IDDM, the question is why 
the diseases do not always coincide. At least three possibili- 
ties can be suggested. First, neurons and/3 cells may express 
forms of GAD that differ antigenicaUy. Second, the accessi- 
bility of GAD to the immune system may differ in the two 
tissues because neurons, but not/3 cells, are protected by the 
blood brain barrier. Third, the humoral and/or cellular im- 
mune responses to GADrs may differ in the two diseases. 
The demonstration that/3 cell and neuronal forms of GAD 
are identical with regard to antigenicity and sequence (3, 15-17) 
seems to exclude the first possibility, although minor differ- 
ences in posttranslational modification have not been ruled 
out. The two tissues clearly do differ in their vulnerability 
to immune system interactions. In addition to their seques- 
tration behind the blood brain barrier, neurons do not ex- 
press MHC class I antigens (18). In contrast,/3 cells are readily 
accessible to circulating immunological effectors and express 
MHC class I antigens (19) that can target them for killing 
by cytotoxic T lymphocytes (20, 21). These differences can 
explain why SMS is a rare disease in individuals afflicted with 
IDDM, but not why only 30-40% of SMS patients develop 
diabetes. To explain the low penetrance of IDDM in SMS, 
we hypothesize that the immune mechanisms in SMS and 
IDDM reflect distinct recognition of GAD. 
To assess possible differences in recognition of GAD, we 
have begun to characterize the target epitopes of the humoral 
autoimmune r sponse in the two diseases. The predominant 
epitopes for GAD6s autoantibodies a sociated with IDDM 
are conformational nd localized to the COOH-terminal and 
middle regions of the GAD6s molecule (22). In rare cases 
where IDDM autoantibodies recognize the denatured 
GAD6s molecule on Western blots, the epitope has been 
localized to the COOH-terminal domain and may represent 
the phenomenon ofrestricted epitope spreading (22, 23). We 
and others have shown that GAD autoantibodies in SMS react 
with the denatured antigen on Western blots (7, 13, 24) sug- 
gesting that the humoral autoimmune response to GAD6s 
differs in IDDM and SMS. In the present study we have charac- 
terized an epitope that clearly distinguishes SMS autoanti- 
bodies from those of IDDM. 
Materials and Methods  
Antisera. Sera were obtained with informed consent from 33 
SMS patients identified at the Mayo Clinic (Rochester, MN) during 
the period of 1989-1992, and from two patients who attended the 
University of California, San Francisco (UCSF) Neurology Clinic 
during the period of 1991-1993. The patients were diagnosed using 
uniform standardized criteria developed at the Mayo Clinic and 
adapted at UCSF (14). The age, sex, age at onset of SMS, and the 
coexistence with other autoimmune disorders, including IDDM, 
are shown in Table 1. Control human sera included: (a) Sera from 
11 newly diagnosed IDDM patients. This group included aserum 
(no. 675, "IDDM serum 2" in this study, female aged 11 years) 
that is used as a standard for quantitative analyses of GADrs au- 
toantibodies by several laboratories (9, 25, 26) and has an arbitrary 
value of 10 in our GADrs antibody assay (26). The remaining sera 
in this group were from 10 individuals selected for having the highest 
GAD~s antibody reactivity amongst 143 newly diagnosed IDDM 
patients collected from the USA and Scandinavia (Table 2). (b) Sera 
from 10 healthy controls (female/male IF/M] = 3:7; mean age _+ 
SD = 29.8 _+ 4.1; range 22-34). (c) Sera from 10 patients diag- 
nosed at UCSF with polyendocrine autoimmune disorder but not 
SMS (F/M = 9:1; mean age • SD = 45.7 • 19.5; range 31-75). 
Each autoimmtme disorder coexisting in the SMS patients was rep- 
resented inat least one of these control patients. Eight of the poly- 
endocrine control patients had IDDM (duration 0-31 yr; mean 
_+ SD 12.6 _+ 12.1) and six of those were GADrs antibody posi- 
tive (Table 2). 
Rabbit antisera 1267 and 1701 were raised against a 19-amino 
acid peptide derived from the COOH terminus of rat GAD67. 
Both sera react equally weU with rat and human GAD65 and 
GAD67 (3, 27). Rabbit antiserum 2001 was raised against a pep- 
tide corresponding to residues 83-93 of human GAD6s. The 
mouse monoclonal antibody GAD6 (28) is specific for GAD6s (3, 
27) and was kindly donated by Dr. D. Gottlieb (Washington Univer- 
sity, St. Louis, MO). The mouse hybridoma GAD1 (29) was ob- 
tained from the American Type Culture Collection (Rockville, MD). 
Immunoprecipitation Analyses. GAD~s autoantibodies were ana- 
lyzed by a quantitative immunoprecipitation assay using [3SS]me- 
thionine labeled rat GAD65 transiently expressed in COS-7 cells 
as described in detail elsewhere (26). Human sera were analyzed 
at dilutions of 1:10, 1:100, 1:1000, 1:10,000, and 1:100,000, and 
resulting immune complexes were isohted on protein A-Sepharose 
(Pharmacia LKB, Piscataway, NJ) and analyzed by SDS-PAGE. 
Seropositivity was scored on the basis of a visible GADrs signal 
obtained by analyses using a model 425 Phosphor-Imager (Molec- 
ular Dynamics, Inc., Sunnyvale, CA). Thus, each immunoprecipi- 
tare was quantitated by phosphorimaging with IDDM serum 2 
(no. 675) serving as a positive standard. GADrs antibody values 
were calculated using the formula: 10 x [(value for the GAD~s 
immunoprecipitate band in an unknown serum subtracted by value 
for background area of identical size)/(value for IDDM serum 2 
subtracted by value for background area of identical size)]. This 
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Table 1. GAD6s Antibodies and ICA in 35 SMS Patients 
SMS Age at 
Patient serum SMS age 
No. Sex sampling at onset 
IDDM/age 
at onset ICA 
Other auto- 
antibodies/ 
disorders 
GAD6sAb 
IMP titer 
1" F 45 34 no* 
2 F 48 43 no s 
3 F 40 36 noS 
4 F 41 39 no 
5 F 51 48 49 
6 F 35 34 34s 
7 F 34 26 noS 
8 M 40 27 no 
9 M 40 36 noS 
10 M 64 56 noS 
11 F 34 29 no 
12 F 43 40 no 
13 M 57 <47 no 
14 F 38 34 33s 
15 F 59 50 57 
16" F 44 42 no 
17 P 36 32 16 
18 F 39 37 35 
19 F 54 44 noS 
20* M 36 35 no 
21 M 63 59 63 
22 F 65 64 55s 
23 F 56 <52 Pre-DM 
52 
24 M 68 61 Pre-DM 
60 
25 F 39 39 No 
26 M 49 47 Pre-DM 
49 
27 F 50 N/A no 
28 F 40 39 no 
29 M 50 47 no 
30 F 50 39 39 
31 M 70 67 70 
32* F 47 43 no 
33 F 45 37 no 
34* F 50 46 no 
35 F 60 48 no 
JDF units 
8,620 
819 
3,940 
8,620 
819 
8,620 
1,610 
1,800 
>10,000 
171 
1,800 
8,620 
1,087 
554 
2,660 
7,570 
253 
3,940 
345 
>20,000 
1,800 
374 
>10,000 
Neg. 
1,210 
115 
3,110 
2,370 
2,370 
>I0,000 
5,110 
>10,000 
>10,000 
>10,000 
5,110 
yes 
yes 
yes 
yes 
yes 
yes 
N/A 
yes 
N/A 
N/A 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
N/A 
yes 
N/A 
yes 
yes 
yes 
yes 
yes 
None 
yes 
N/A 
N/A 
yes 
yes 
yes 
yes 
N/A 
N/A 
5,260 
495 
10,150 
13,310 
2,920 
5,440 
7,040 
930 
16,620 
578 
3,460 
11,140 
1,166 
1,260 
2,870 
3,380 
444 
2,920 
4,100 
65,700 
1,654 
1,551 
10,660 
44 
3,450 
173 
6,090 
2,600 
1,338 
9,720 
1,561 
20,280 
9,500 
1,561 
752 
* African Americans, the remaining patients are caucasian. 
* Father had NIDDM. 
$ IDDM in first degree relative(s). N/A, information not available. 
IMP, immunoprecipitation. 
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Table 2. Summary ofGADrs Antibody Titers in SMS, 1DDM, and Polyendocrine Autoimmune Disorder (PE) Patients 
Sex Age Age GAD6sAb IMP titer GAD6sAb IMP titer 
n F/M mean _+ SD range median range 
tMt 35 25/10 48 _+ 10.1 34-70 2920 44-65,700 
IDDM 10" 2/8 4.6 _+ 5.0 0.9-15 20.3 14.7-36.6 
PE 6* 5/1 48 _+ 19 11-75 8.2 1.3-15.9 
* Selected for having the highest GAD6s antibody titer amongst 143 newly diagnosed IDDM patients, 115 (80%) of whom were positive for GAD6sAb 
with a median titer of 1.7. 
t From a group of 10 PE patients, 6 of whom were GADrsAb positive. 
IMP, immunoprecipitation. 
assay was used in the first GAD antibody workshop (Orlando, FL, 
April 1993) and yielded 100% sensitivity and 100% specificity. 
Expression Systems and Protein Synthesis. The generation of 
recombinant baculovimses harboring either at GAD6s (4), human 
GAD65, or human GAD67 (22) was described earlier. A recom- 
binant baculovirus for expressing an NHz-terminal deletion mu- 
tant of rat GAD6s lacking the first 101 amino acids was generated 
by first making a 2-kb deletion mutant by oligonucleotide-directed 
mutagenesis (5), cloning this mutant into the EcoRI site of 
pBhescript (Stratagene, La Jolla, CA), from which it was released 
by tmaI and NotI digestions, and finally inserting the mutant cDNA 
into the SmaI and NotI sites of the baculovirus expression vector 
pVL1393 (Invitrogen, San Diego, CA). A clone containing the sense 
orientation for the A1-101 mutant of rat GAD6s was used in a cal- 
cium phosphate cotransfection with wild-type Autographa c lifor- 
nica nuclear polyhedrosis virus. Recombinant viruses were isolated 
as described (30). Recombinant proteins were expressed from the 
baculovirus constructs in Sf9 cells. Generation of NHz-terminal 
deletions of a rat GAD6s mutant in which cysteines at positions 
30 and 45 have been substituted with alanines, and insertion of 
the mutants into the COt-cell expression vector pSV-SPORT 
(GIBCO BILL, Gaithersburg, MD) were described earlier (5). De- 
letion mutants lacking the first NHz-terminal 8 (A1-8), 15 (A1- 
15), and 23 (A1-23) amino acids of rat GADr5, respectively, were 
produced by transient transfection ofCOS-7 cells using lipofecta- 
mine (GIBCO BRL). 
For Western blot analyses, Sf9 or COS-7 cells expressing 
GAD6s, GAD67, or NHz-terminal deletion mutants of GAD6s 
were washed twice in cell harvest buffer (10 mM Hepes/NaOH, 
pH 7.4, 150 mM NaC1, 10 mM benzamidine/HC1, 0.1 mM PMSF), 
and lysed in HMAP buffer (10 mM Hepes/NaOH, pH 7.4, 1 mM 
MgC12, 1 mM aminoethylisothiouranium bromide hydrobromide 
[AET], 0.2 mM pyridoxal 5'phosphate [PLP]) containing 1% Triton 
X-114, and 0.1 mM PMSF at 4~ After centrifugation at 264,000 
g, 4~ for 30 min, the superuatant was collected and prepared 
for SDS-PAGE by boiling for 3 min in SDS sample buffer at a final 
concentration of 8 mM Tris/HC1, 15% sucrose, 2% SDS, 5% 
B-mercaptoethanol, and 0.006% bromophenol b ue. 
A 58-kD tryptic fragment containing the COOH terminus was 
generated from rat or human GAD6s produced in Sf9 cells. Ap- 
proximately 60 x 106 Sf9 cells were harvested 72 h after infec- 
tion with the appropriate baculovirus. The cell pellet was extracted 
in 4 ml of HMAP buffer supplemented with 1% Triton X-114 and 
0.1 mM PMSF for 1 h on ice. The lysate was diluted with 21.6 
ml of HEMAP (HMAP supplemented with 1 mM EGTA) and 
treated with 5.4 ml of N-tosyl-t-phenylalanine-chloromethylketone 
(TPCK)-treated trypsin (2 mg/ml; Sigma Chemical Co., St. Louis, 
MO) for 20 min at 0~ The reaction was quenched by adding 
400/~1 of 100 mM PMSF and 6.8 ml 5 x SDt-sample buffer. This 
material was used for Western blot analysis. 
The approximate location of the tryptic cleavage site was esti- 
mated based on the relative molecular weight of the fragment ob- 
tained by SDS-PAGE, followed by sequencing of the NH2 ter- 
minus of the isolated peptide. Approximately 300 x 106 Sf9 cells 
infected for production of human GADrs were harvested and sus- 
pended in HMAP buffer containing 1% Triton X-114 and 0.1 mM 
PMSF, and incubated for 1 h on ice. The cells were then 
homogenized using a Tissumizer homogenizer (Tekmar Co., Cin- 
cinnati, OH) for 30 s on ice. The cell lysate was centrifuged at 
100,000 g and the supernatant was applied to a phenyl-Sepharose 
CD4B column (Pharmacia LKB) preeqnilibrated in buffer A (50 
mM potassium phosphate, pH 7.0, 10 mM dithiothreitol [DTT], 
1 mM AET, 0.2 mM PLP) containing 2 M ammonium sulfate, 
then washed with 5 column volumes of buffer A containing 2 M 
ammonium sulfate. The protein was eluted using buffer A and a 
gradient with initially 0% Triton X-100 and 1.5 M ammonium 
sulfate, and finally 2% Triton X-100 and 0 mM ammonium sul- 
fate. Fractions containing GAD activity were pooled and subjected 
to immunoat~nity chromatography using the GAD1 monoclonal 
antibody as described (27) except that the gel matrix was washed 
sequentially with 10 volumes of buffer B (10 mM Hepes/NaOH, 
pH 7.4, 10 mM DTT, 1 mM AET, 0.2 mM PLP), 10 volumes of 
buffer B with 0.5 M NaC1 and 10 volumes of buffer B before lu- 
tion of GAD6s in 1-ml aliquots of buffer A at pH 11 and neutral- 
ized in 100 pl 1M potassium phosphate pH 6.5, 0.2 mM PLP. Pro- 
tein concentrations were determined using Coomassie Plus protein 
reagent (Pierce, Rockford, IL), using BSA as a standard. Purified 
human GAD6s (81 #g/ml, 100 #1) was treated with 5 #1 of 0.2 
mg/ml TPCK-treated trypsin (1 #g in 5/zl) for 1 h at 0~ The 
reaction was quenched by adding 10 #1 of 100 mM PMSF and 
freezing at -20~ The sample (13 pmol of the 58-kD protein) 
was subjected to preparative SDS-PAGE and blotted to Pro Blott 
polyvinylidene difluoride (PVDF) membrane (Applied Biosystems, 
Inc., Foster City, CA). A slice of PVDF paper containing the 58 
kD fragment was used for gas phase sequencing using a gas phase 
sequencer (model 470A; Applied Biosystems, Inc.). The phenylthio- 
hydantoin (trrH)-derivatives were identified by reverse-phase HPLC 
using an on-line PTH analyzer (model 120A; Applied Biosystems, 
Inc.). Electrophoresis, blotting, and sequencing were carried out 
at the Biomedical Resource Center, UCSF. The results were con- 
sistent with the generation of two fragments by cleavage at either 
position 69 (lys) or 70 (arg). 
Western Blot Analyses. To compare serum IgG specificities for 
GAD67, GAD65, the 58-kD fragment of GAD6s, and deletion mu- 
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tants of GAD6s, it was essential toload equal amounts of each pro- 
tein on the gel. A preparation ffull-length rat or human GAD6s 
was chosen as an arbitrary standard and titrated on Western blots. 
Each protein preparation was titrated and calibrated against this 
standard to obtain an identical signal on Western blots immuno- 
stained with rabbit 1267 antiserum, which is equally reactive with 
both GAD67 and GAD6s (27). Finally, the concentrations of 
different proteins which consistently gave a signal equivalent to 
that of the GAD6s standard were tested several times on the same 
blots, to ensure quivalent signal intensities. Equal amounts of full- 
length GAD67, GAD6s, 58-kD trypsin fragment of GAD6s, or de- 
letions mutants of GAD6s were then subjected to SDS-PAGE, 
blotted to Immobilon PVDF transfer membrane (Millipore Corp., 
Bedford, MA) and analyzed for binding of human IgG and animal 
antiserum IgG after dilution of sera as described earlier (27). In 
some xperiments, human sera were preabsorbed using a homoge- 
nate of noninfected SDcells as indicated. Sf9 cells were homogenized 
in HMAP buffer (107 cells/ml) using a Tissumizer homogenizer 
(Tekmar Co.) for 1 rain on ice. The homogenate was centrifuged 
at 264,000g. Sera were incubated with 0.2 vol of Sf9 cell superna- 
tant for 16 h at 4~ diluted, and used for immunostaining of 
Western blots (27). 
Synthesis ofPeptides for Blocking Studies. Peptides of 20 residues, 
spanning amino acids 1-119 of the human GAD6s molecule (17), 
and each overlapping the next sequence by 9 amino adds, were 
synthesized by a multiple peptide synthesizer (Advanced Chem- 
tech, Louisville, KY), using fluorenylmethoxycarbonyl (FMOC)- 
protected amino acids and amino acid resins (Bachem California, 
Torrance, CA). Side chain deprotection a d cleavage from the resin 
were performed with trifluoroacetic a id/anisole/dimethylsulfide 
(9:0.5:0.5 vol/vol), and the Peptides were extracted with ether. Pep- 
tide identity was confirmed by protein sequence analysis with a 
Protein Sequencer (Applied Biosystems, Inc.). For blocking studies, 
the peptides were solubilized in TBS/Tween-20 buffer (20 mM 
Tris/HC1, pH 7.4, 150 mM NaC1, and 0.1% Tween-20) to a con- 
centration of0.5 mg/ml. All Peptides, except no. 8, dissolved readily 
in this buffer. Because peptide 8(residues 78-97) was only partially 
soluble, itwas used as a saturated solution which effectively blocked 
the binding of rabbit antiserum 2001 (reactive with residues 83-93 
in human GAD6s). 
Dot Blot Analyses. Human GAD6s was extracted from SD cells 
and isolated to ~95% purity by immunoafl~nity chromatography 
as described previously (27). Purified GAD6s at a concentration f 
55/~g/ml in 100 mM potassium phosphate, 0.2 mM PLP, 1 mM 
AET, 0.1% SDS, was boiled for 3 rain before spotting (0,2 #g) 
on Immobilon PVDF transfer membrane (Millipore Corp.) using 
a BILL HybriDot Manifold (GIBCO BILL). The PVDF membrane 
was blocked with TBS/Tween-20 buffer containing 3% milk pro- 
tein for 1 h at room temperature. The membranes were incubated 
with sera (diluted in TBS/Tween-20 buffer containing 2% BSA) 
for 1.5 h at room temperature; after three washes of 5 rain in 
TBS/Tween-20, they were incubated with alkaline phosphatase- 
conjugated goat anti-human IgG (Zymed Laboratories, Inc., South 
San Francisco, CA) or anti-rabbit IgG (Zymed Laboratories, Inc.) 
at a dilution of 1:500 in 3% milk/TBS/Tween-20 buffer for 1 h 
at room temperature. After two washes of 5 rain in TBS/Tween- 
20 and one in TBS buffer, the blots were developed by incubation 
for 3 rain in 0.4 mM 5-bromo-4-chloro-3-indolyl phosphate and 
0.4 mM nitro blue tetrazolium in 150 mM Tris-HC1, pH 9.5, 100 
mM NaC1, and 5 mM MgC12. 
Human sera (SMS, IDDM, polyendocrine, and normal sera) were 
diluted 1:100, 1:200, and 1:500 in TBS/Tween-20 buffer, 2% BSA. 
Rabbit antisera 1701 and 2001 were diluted in the same buffer, 
1:200,000 and 1:2,000, respectively. For Peptide blocking experi- 
ments, diluted sera were incubated overnight at 4~ with either 
a mixture of Peptides (0.3/~g/#l each), an individual peptide (0.3 
#g/~l), human GAD6s (5.5/~g/ml), or no additive, before incu- 
bation with dot blots of purified human GAD6s. 
Analyses of lslet Cell Cytoplasmic Antibodies (ICA). ICAs were 
analyzed by indirect immunofluorescence using frozen sections of 
human pancreas from blood group O-positive donors of cadaveric 
kidneys (31). Serum samples were titrated and end point titers were 
defined as the highest dilution of detectable ICA-staining. Positive 
samples were expressed in Juvenile Diabetes Foundation 0DF) units 
by comparing their end point dilution to a standard calibration curve 
using the international JDF reference s rum provided by the Im- 
munology of Diabetes Workshops. This assay has performed in 
category A in the ICA proficiency program conducted under the 
auspices of the Immunology of Diabetes Workshops (32). 
HLA-typing. DRB1, DQB1, and DQA1 typing was performed 
with a PCR dot blot technique as described (33, 34). 
Results 
SMS Sera Contain Higher Levels of Immunoprecipitating 
GAD6s Autoantibodies than IDDM Sera. Sera from 35 SMS 
patients were analyzed for GAD6s autoantibodies byimmu- 
noprecipitation f [3SS]methionine-labded Triton X-114 de- 
tergent phase xtracts of COS-7 cells expressing rat GAD6s 
(Table 1). Anti-GAD6s IgG titers, quantified in serially 
diluted sera by phosphorimager analyses, were orders of mag- 
nitude higher in SMS sera (Tables 1 and 2) than in IDDM 
sera and sera from patients with polyendocrine autoimmune 
disorder (Table 2). Thus, the GAD6s binding capacity of 
SMS IgG is orders of magnitude higher than that of IDDM 
IgG. Titers of ICA in the SMS patients were also higher (Table 
1, median titer 2660 JDF units) than in 327 ICA-positive 
newly onset IDDM sera analyzed by the same assay (median 
titer 110JDF units) (31). The correlation coefficient between 
ICA and GAD6s autoantibody titers in the 35 SMS patients 
was 0,77. 
SMS Epitopes Recognized inDenatured GAD6s, Are Absent 
in GAD67, and Distinct from IDDM Epitopes. The 35 SMS 
sera were analyzed by immunoblotting for reactivity with 
equal amounts of denatured GAD6s and GAD67. Additional 
sera were tested from 11 IDDM patients, 10 healthy individ- 
uals, and 10 patients with polyendocrine autoimmune dis- 
order without SMS. No serum IgG bound to human or rat 
GAD67 on Western blots (Fig. 1 A, lanes 3, 5, 7, 9, 1I). 
IgG in all SMS sera reacted specifically with GAD65 (Fig. 1 
A, lanes 4, 6, 8), but no reactivity was found in the sera from 
patients with IDDM (Fig. 2, lanes 22 and 25), polyendo- 
crine autoimmunity (Fig. 1, lane I0), or healthy control sub- 
jects (Fig. 1, lane 12; Fig. 2, lanes 28 and 3I) at the same 
dilution. To analyze whether the lack of reactivity of IDDM 
sera with GAD6s on Western blots was due to low titers 
rather than differences inepitope recognition, the IDDM sera 
used in this study were also analyzed at lower dilutions to 
obtain a final GAD6s antibody titer of 4 and compared with 
SMS sera analyzed at the same titer. To avoid nonspecific 
binding of SD cell proteins at high IgG concentrations, the 
sera were preabsorbed with noninfected Sf9 cell lysates. At 
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the low dilutions, IDDM sera still failed to react with dena- 
tured GAD6s on Western blots (Fig. 1 B). The results dem- 
onstrate that SMS autoantibodies are directed at epitope(s) 
in the GAD6s molecule that are resistant to denaturation by
SDS and are therefore likely to becontinuous. Reactivity with 
these GAD6s-specific epitope(s) qualitatively distinguishes Linear 
SMS autoantibodies from anti-GAD6s autoantibodies found NH2- terminal 
in IDDM and polyendocrine autoimmune disorder in the ab- Pattern epitope 
sence of SMS. 
SACS Autoantibodies Recognize Epitopes inthe NH2-terminal 
Region of Denatured GADts. Since GADts differs most IA yes 
significantly from GAD67 in the first 95 amino acids, we 
speculated that this region might harbor GADts-specific IB yes 
SMS epitopes recognized by immunoblotting. To address this 
possibility, all sen were analyzed in parallel for reactivity with 
equal amounts of full-length rat GADts, a 58-kD tryptic 
fragment of rat GAD6s lacking the first 69 or 70 amino 
acids, and a 55-kD deletion mutant lacking the first 101 amino II yes 
Table 3. Distribution of SMS-Patients According to 
Patterns of Epitope Recognition in Denatured GAD65 
Recognition of epitopes 
NH2- Epitope 
terminal in a SMS- 
epitope A101 patients 
predominant mutant no. 
yes no 1,2,5,8,17, 
22,27,28,31 
yes weak 7,10,11,13 
14,15,16,19 
21,23,24,25 
26,29,30,35 
no strong 3,4,6,9,12, 
18,20,32,33, 
34 
Figure 1. SMS sera recognize GADs but not GAD67 on Western blots 
and this reactivity distinguishes SMS from IDDM and polyendocrine an- 
toimmunity in the absence of SMS. (A) Lysates of Sf9 cells expressing 
human GAD67 (lanes I, 3, 5, 7, 9, 11) or GADts (lanes 2, 4, 6, 8, 10, 
12) produced from a baculovirus expression system were subjected to SDS- 
PAGE, blotted to a PVDF membrane, and immunostained using the human 
sera indicated (PE, polyendocrine patient serum; NHS, normal human 
serum) at dilutions of 1:500 and the rabbit anti-GAD antiserum 1267 at 
dilution 1:100,000. (B) Lysates of SD cells expressing human GAD67 (hnes 
I, 3, 5) or GADts (lanes 2, 4, 6) immunostained with SMS and IDDM 
sera preabsorbed to a Sfg-ceU lysate and diluted (SMS22, final dilution 1:388; 
IDDM1, final dilution 1:9) to obtain a titer ofapproximately 4 for GADes 
antibodies. Immunostaining with the 1267 antiserum (dilution 1:20,000) 
is shown in lanes 1 and 2. 
acids of rat GAD6s (GADtsAI-101) (Fig. 2 and Table 3). 
Among the SMS sera, two major patterns of reactivity were 
observed. The majority (25 of 35, or 71%) of SMS sera ex- 
hibited pattern I, in which reactivity with fuU-length 
GAD65 was much stronger than with both the 58- and 55- 
kD fragments. This serological pattern suggests that the 
NHz-terminal 69 or 70 amino acids in rat GAD6s harbor a 
major linear epitope(s) Fig. 2, lanes 4-15, and Table 3). 
Among the pattern I sera, IgG in 9 (pattern IA) reacted 
strongly with the fulblength GADts protein, but did not 
recognize the 58- and 55-kD fragments, demonstrating that 
the recognition of denatured rat GAD6s was limited to the 
first 69 or 70 amino acids (Fig. 2, lanes 4-9). IgG in the 
remaining 16 SMS sera of the pattern I group (pattern IB) 
reacted strongly with the full-length protein, and were sig- 
nificantly less reactive with the 58- and 55-kD fragments. 
This result again suggested IgG that recognized a major 
epitope in the first 69 or 70 amino acids but, in addition, 
minor epitope(s) further downstream in GADts (Fig. 2, 
lanes 10-I5, and Table 3). Thus for 71% of the SMS sera 
(pattern IA and B), the major epitope recognized in ena- 
tured rat GADts resides in the first 69 or 70 amino acids. 
Pattern II reactivity, found in 10 of 35 SMS sera (29%, pat- 
tern II), was distinctly different in that reactivity with both 
the 58-kD tryptic fragment and the 55-kD deletion mutant 
was only minimally less than reactivity with the full-length 
protein (Fig. 2, lanes 16-21, and Table 3). Thus 29% of 
the SMS patients had autoantibodies that recognized an ad- 
ditional major epitope(s) further downstream in the dena- 
tured GADbs molecule. In sum, residues 1-69 or 1-70 in rat 
GADbs contribute to a linear epitope(s) that is recognized 
by IgG in serum of all SMS patients, and residues COOH 
terminal to amino acid 101 in rat GADts contribute to a 
second antigenic region that is recognized by IgG in only 
some SMS patients. 
600 NH2-terminal Linear GAD65 Epitope in Stiff-Man Syndrome 
Figure 2. SMS sera show two patterns of reactivity 
with 58- and 55-kD COOH-terminal fragments of 
rat GADds. Full-length GADds, a 58-kD tryptic frag- 
ment of rat GAD65, and a 55-kD NH2-terminal de- 
letion mutant of rat GADds lacking amino acids 
1-101, were subjected to SDS-PAGE, blotted to PVDF 
membrane, and immunostained usingthe sera at the 
following dilutions: SMS 1, 12, 18, 30 at 1:500, SMS 
2, 21 at 1:200, and IDDM and NHS at 1:500. SMS 
sera 1, 2, 21, and 30 (pattern I) recognize a major epi- 
tope NH2-terminal to amino acid 69/70, whereas 
SMS sera 12 and 18 (pattern II) also recognize a strong 
epitope COOH-terminal to amino acid 101. Among 
pattern I sera, two subpatterns are observed. In pat- 
tern IA, the sera only recognize the fill-length pro- 
tein. In pattern I13, the sera recognize a weaker epi- 
tope COOH-terminal to amino acid 101. 
The Principal NHz-terminal Epitope Resides in the First Eight 
Amino Acids. To further localize the SMS epitope(s) in the 
NH2-terminal region, we synthesized ten peptides, each 20 
amino acids long, spanning residues 1-119 in the GAD6s 
molecule and overlapping each other by 9 amino acids. We 
tested the ability of the peptides to block the dot blot reac- 
tivity of SMS IgG with denatured GAD6s. The first series 
of experiments tested three mixtures of peptides, peptides 
1-3 (spanning residues 1--42), peptides 3-6 (residues 34-75), 
and peptides 7-10 (residues 67-119). The mixture of pep- 
tides 1-3 completely blocked the reactivity of pattern IA sera, 
significantly blocked pattern 1t3 reactivity, and partially blocked 
pattern II reactivity. These results are consistent with recog- 
nition of an epitope in the first 42 amino acids by both pat- 
tern I and pattern II sera. The mixture of peptides 4-6 did 
not affect he binding of SMS IgG to denatured GAD6s (not 
shown). The mixture of peptides 7-10 partially blocked the 
reactivities of both pattern I and pattern II sera. We next 
analyzed the ability of individual peptides 1, 2, 3, 7, 8, 9, 
and 10 to block the binding of SMS IgG to denatured 
GAD6s. These experiments revealed that only peptide 1 of 
the 1-3 mixture inhibited the binding of SMS IgG to human 
GAD6s (see Fig. 3), suggesting that the first 11 residues of 
the NH2 terminus of GAD6s contribute to an SMS epitope. 
This blocking was specific, because peptide 1 did not block 
Figure 3. An NHz-terminal peptide of GAD,5 specifically blocks the 
binding of SMS sera. Human GADds purified from a baculovirns expres- 
sion system was spotted on a PVDF membrane and incubated with SMS 
sera (all at 1:500 dilution) or serum 1701 (raised to peptide 170, corre- 
sponding to 19 COOH-terminal amino acids in GAD, at a dilution of 
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1:200,000) that had been incubated overnight with or without he indi- 
cated peptides or human GADds. Peptide 1 completely blocks the reac- 
tivity of serum 1 (pattern IA), significantly inhibits the reactivity of serum 
11 (pattern IB), partially inhibits the reactivity of serum 12 (pattern II), 
but fails to inhibit serum 1701. Peptide 2 dues not inhibit binding of any 
of the sera and peptide 170 only inhibits binding of the serum 1701, which 
was raised against it. 
Figure 4. SMS sera recognize an epitope lo- 
cated in the first eight NH2-terminal mino 
acids. Full-length rat GAD6s and short dele- 
tion mutants lacking 8 and 15 amino acids, 
respectively, were subjected to SDS-PAGE, 
blotted to PVDF membranes, and immuno- 
stained with SMS sera t the following dilu- 
tions: SMS 1, 7, 9, 12, 30 at 1:500 and SMS 
22 at 1:120. All the sera show identical signal 
or lack of signal with the 1-8 and 1-15 dele- 
tion mutants suggesting that they react equally 
well with both mutants and that he NHz- 
terminal epitope resides in the first eight 
residues, whereas residues 9-15 do not con- 
tribute to the epitope. 
the binding of rabbit IgG raised against either a COOH- 
terminal peptide (serum 1701, Fig. 3, panels 25/26) or a pep- 
tide encompassing residues 83-93 in the NH2-terminal re- 
gion (serum 2001, not shown). Each of these antisera were 
blocked by the peptide against which they were raised (Fig. 
3, panels 31/32 and results not shown). Only peptide 7, in 
the mixture 7-10, caused any block of the reactivity of SMS 
sera. However, blocking by peptide 7 was not specific be- 
cause it also inhibited the reactivity of several rabbit antisera 
raised against irrelevant peptides (not shown). The reason 
for nonspecific inhibition by peptide 7 of IgG binding to 
GAD65 on dot blots is unclear. This activity was not found 
with peptides 6 and 8, which together account for all but 
two of the amino acids in peptide 7. Thus, among the NH2- 
terminal peptides spanning the first 119 amino adds, only 
peptide 1 specifically blocked the pattern I reactivity of SMS 
IgGs and partly inhibited the reactivity of pattern II SMS 
IgGs. This result is consistent with a major linear NH2- 
terminal SMS epitope residing in the first 11 amino acids of 
GAD65. 
To further analyze the reactivity of SMS IgG with the 
NH2-terminal region f GAD6s, deletion mutants lacking 
the first 8 and 15 amino acids of rat GAD65, respectively, 
were analyzed by immunoblotting for interaction with SMS 
IgG (Fig. 4). These experiments demonstrated that pattern 
I sera reacted either very weakly (pattern IB) or not at all 
(pattern IA) with both the A1-8 and A1-15 deletion mu- 
tants (Fig. 4, lanes 4-15). In contrast, pattern II sera recog- 
nized both deletion mutants (Fig. 4, lanes 16-21). All of the 
SMS sera either failed to react with both of the short dele- 
tion mutants or showed equal reactivity to both of them (Fig. 
4), indicating that the NH2-terminal linear epitope recog- 
nized by SMS sera resides in amino acids 1-8 and that amino 
acids 9-15 do not contribute to this or other SMS epitopes. 
The results of the peptide blocking experiments and anal- 
yses of deletion mutants localize the NH2-terminal epitope 
recognized by SMS sera to the first 8 amino acids. 
HLA-DRBl*0301, DQB1 "0201 Is the Predominant Haplo- 
type among Patients of Pattern I Seropositivity. Many autoim- 
mune diseases, including IDDM, are strongly associated with 
certain MHC class II haplotypes. Thus >/95 % of IDDM pa- 
tients carry the HLA-DRBI*0301, DQBI*0201 (D1L3, 
DQw2) and/or DRBI*0401, DQBI*0302 (DR4, DQ8) sus- 
ceptibility haplotypes (35). To assess whether SMS and IDDM 
have similar HLA-association, we obtained lymphocytes from 
12 of the SMS patients, 9 with serological pattern I and 3 
with serological pattern II. (Table 4, and Lennon, V., S. Baek- 
keskov, T. Bugawan, and H. Erlich, manuscript in prepara- 
tion). 9 of the 12 SMS patients carried the IDDM associated 
allele DQw2 (DQBI*0201), 8 on the DIL3 (DRBI*0301) 
and one on the DR7 (DRBI*0701) haplotype. Amongst he 
DQw2 positive patients, 8 (4 of whom were homozygous) 
had serological pattern I reactivity and one had pattern II 
reactivity. The only non-DQ2 positive patient with pattern 
I was positive for the IDDM associated haplotype DR4, DQ8 
(Table 4). Thus all nine patients with serological pattern I 
but only one of the three patients of pattern II carried an 
IDDM associated haplotype (Table 4). One of the pattern 
II patients carried the DRBl*1501, DQBI*0603 (DR2, 
DQw6) haplotype, which is protective for IDDM (36). The 
DR3, DQw2 IDDM-associated haplotype is particularly 
abundant, whereas the DR4, DQw8 IDDM-associated haplo- 
type is rare in the pattern I SMS patients (Lennon V., S. Baek- 
keskov, T. Bugawan, and H. Erlich, manuscript in prepa- 
ration). 
Table 4. DR and DQ Haploty~s ofSMS Patients 
SMS 
patient 
no.  DRBI DQB1 
GAD6sAb 
Western blot 
pattern 
1 0701 
2 0301 
3 1601 
4 1501 
6 0301 
7 0301 
8 0404 
11 0301 
14 0301 
15 0301 
19 0301 
30 0301 
1302 0201 
0301 0201 
1401 0502 
1301 0603 
0901 0201 
0401 0201 
1103 0302 
0301 0201 
0401 0201 
0400 0201 
0301 0201 
0301 0201 
0604 
0201 
0503 
0602/O3 
0303 
0301/02 
0301 
0201 
0302 
0301 
0201 
0201 
I 
I 
II 
II 
II 
I 
I 
I 
I 
I 
I 
I 
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Figure 5. Schematic drawing of the GAD65 molecule showing loca- 
tion of humeral epitope areas, membrane anchoring regions, and proteo- 
lytic hot spot. 
Discussion 
Linear Epitopes in GAD6s. We have identified a linear 
NH2-terminal epitope in the autoantigen glutamic acid 
decarboxylase, GAD6s, that is specifically recognized by au- 
toantibodies in serum of patients with SMS (Fig. 5). This 
epitope is not recognized by anti-GAD6s autoantibodies that 
are associated with 3 ceU destruction and development of 
insulin-dependent diabetes in the absence of SMS (Fig. 5). 
Hence specifidty for the linear NH2-terminal epitope distin- 
gnishes IgG autoantibodies of SMS patients from those of 
IDDM patients. Antibodies of this specificity may be impor- 
tant for the prediction and diagnosis of SMS. 
A recent Western blot study of SMS antibody reactivity 
with GAD6s used bacterially expressed recombinant frag- 
ments of rat GAD6s coupled to a maltose binding protein 
(24). A fragment containing residues 475-585 of rat GAD6s 
was recognized much more strongly than full-length GAD6s, 
but the reactivity was abolished by deleting either esidues 
475-483 or residues 582-585. Based on these results, the 
authors concluded that the major SMS epitope recognized 
on Western blots is not linear but rather conformational and 
generated by refolding of the denatured amino acid 475-585 
fragment on nitrocellulose. To explain why a partial frag- 
ment was more reactive than wild-type rat GADes, the 
authors uggested that he conformational epitope in residues 
475-585 is partly cryptic in the native molecule (24). Con- 
sistent with our results, Butler et al. (24), also reported that 
SMS antibodies recognize rat GAD6s fragments containing 
amino acids 1-95 or 1-195 on Western blots, albeit more 
weakly than the 475-585 fragment. 
The pattern II specificity defined in our study clearly 
identifies amajor epitope(s) COOH-terminal to residue 101 
in denatured rat GAD6s on Western blots, which may rep- 
resent he nonlinear epitope described by Butler et al. (24). 
However pattern II reactivity only accounted for 29% of the 
SMS sera nalyzed in our study. The remaining 71% of SMS 
sera had a reactivity that was consistent with recognition of 
a dominant NH2-terminal linear epitope but not a major 
epitope further downstream in denatured rat GAD65 on 
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Western blots. The difference between our results and those 
of Butler et al. (24) is not readily explained. Several possibili- 
ties can be suggested. First, we have analyzed all SMS pa- 
tients at the Mayo Clinic and UCSF over the last 5 yr. The 
study by Butler et al. (24) used sera from 30 patients which 
were selected from a cohort of 72 SMS patients by unknown 
criteria; the selection procedure may have favored pattern II
sera. Second, their immunoblotting protocol may enhance 
renaturation f the amino acid 475-585 epitope on Western 
blots. A third possibility is that the coupling of the 475-585 
fragment to a maltose binding protein enhances its refolding 
on nitrocellulose. 
In addition to linear epitopes associated with SMS and 
IDDM respectively (Fig. 5), Ujihara et al. (36) have identified 
a third linear epitope in residues 421-442 in the GAD6s pro- 
tein. This epitope is recognized by IgG in a rare group of 
IDDM relatives that develop high titers of GAD6s autoan- 
tibodies yet carry the HLA-DRBl*1501, DQBI*0603 (DR2, 
DQw6) haplotype which is protective for diabetes. Interest- 
ingly, one of the three SMS patients of pattern II who was 
HLA-haplotyped carried this haplotype. We speculate that 
additional pattern II patients, amongst whom IDDM was 
rare (20%) compared with pattern I patients (44%), may 
carry alleles that are protective for IDDM and that pattern 
II may in some cases include recognition of the epitope de- 
scribed by Ujihara et al. (36). In comparison, none of the 
9 pattern I patients who were HLA-haplotyped were DR2, 
DQw6 positive. Rather they all carried one or two IDDM 
susceptibility alleles and the DR3, DQw2 allele was particu- 
larly abundant (7/9). 
The NH2-terminal linear epitope identified in our study 
is identical in rat and human GAD6s, which overall share 
I>95% sequence homology (17). Although it has been 
reported that SMS sera recognize rat and human GAD6s 
equally well (24), our preliminary results suggest hat the 
downstream epitope(s) may differ between the rat and human 
autoantigen. Thus a 58-kD tryptic fragment of the human 
protein is recognized more strongly on Western blots by some 
pattern IB and pattern II sera than its rat counterpart. Gener- 
ation of mutants of the human protein and expression i cel- 
lular expression systems will be important for characterizing 
the SMS epitope(s) contained inthe 58-kD tryptic fragment. 
SMS Sera Have an Increased GAD Epitope Recognition Com- 
pared with IDDM Sera. Anti-GAD6s autoantibodies differ 
significantly inSMS and IDDM patients with regard to titers 
measured by immunoprecipitation. Titers of autoantibodies 
associated with SMS are orders of magnitude higher than 
in IDDM sera. Thus SMS is characterized by a much stronger 
humoral autoimmune r sponse to GAD6s than is IDDM. 
Is the strong antibody response to GAD6s in SMS a re- 
sult of (a) an increased humoral epitope repertoire in this dis- 
ease compared with IDDM; (b) an enhanced immune response 
to certain epitopes, or (c) a combination of both? Since no 
monoclonal utoantibodies are yet available from SMS pa- 
tients, this question is difficult to address directly. However, 
considerable indirect evidence suggests that the humoral re- 
sponse in SMS sera is more broad than in IDDM. By immu- 
noprecipitation assay, both SMS and IDDM sera recognize 
an NHz-terminal deletion mutant of GAD6s lacking the first 
244 amino acids (22, and Shi, Y., and S. Baekkeskov, unpub- 
lished results). This suggests that IgGs in SMS and IDDM 
sera recognize conformational epitopes in the COOH-terminal 
half of the molecule. In addition, SMS autoantibodies 
specifically recognize the linear NHz-terminal epitope iden- 
tified in this study. Finally, the incidence of GAD67 autoan- 
tibodies in IDDM patients is only 10-20% (8, 9), whereas 
sera of SMS patients generally immunoprecipitate native 
GAD67 (24, 37) albeit less efficiently than GAD6s (24). On 
Western blots, SMS sera react specifically with GAD6s and 
do not recognize GAD67. In sum, the humoral autoimmune 
response in SMS seems to include conformational epitopes 
(detected by immunoprecipitation) as well as linear epitope(s) 
(recognized in Western blots) that are not recognized by 
IDDM sera. It is likely that the stronger antibody responses 
associated with SMS reflect both a broader epertoire of epi- 
topes than is characteristic of IDDM as well as higher affinity 
for shared epitopes. 
The Linear NH2-terminal Epitope Is Upstream from the Mem- 
brane Anchoring Domain and a Proteolytic Hot Spot. We have 
localized the vesicle targeting and membrane anchoring se- 
quences in GAD6s to the second exon of the molecule (5) 
that spans amino acids 25-41 (2). GAD6s has a proteolytic 
hot spot around residues 69-75 encoded by the third exon 
(Fig. 5). GAD6s can be released spontaneously from islet cell 
membranes a a 57-58 kD hydrophilic soluble fragment in 
a time-dependent manner (4). The kinetics of this reaction 
are consistent with an enzymatic leavage in islet cells (4). 
We speculate that this enzymatic activity may also reside in 
neurons and perhaps result in enhanced exposure of the 
NH2-terminal SMS epitope in a 7-8-kD fragment that re- 
mains membrane associated after cleavage. 
All SMS Patients Are Positive for Antibodies to GAD6s. In 
a study of 32 SMS patients from seven different countries, 
which only found GAD autoantibodies in 20 patients (63%), 
it was suggested that SMS patients can be divided into two 
groups based on whether they have GAD autoantibodies or 
not (13). Most of the patients analyzed in our study were 
diagnosed at the Mayo Clinic in Rochester, where the dis- 
ease was discovered and first described by Moersch and 
Woltman (38). Two patients were diagnosed at UCSF using 
clinical diagnostic criteria similar to those of the Mayo Clinic 
(14). All 35 patients were positive for GAD65 autoantibodies 
both in immunoprecipitation and Western blot assays. Our 
results suggest hat a diagnosis of SMS using standardized 
clinical criteria identifies a uniform group of patients with 
strong humoral autoimmunity o GAD6s. A SMS-like dis- 
order associated with breast carcinoma was, however, ecently 
described in four patients who were seronegative for anti- 
GAD6s antibodies but positive for autoantibodies to a second 
synaptic vesicle protein, amphiphysin (39). Thus anti-GAD6s 
autoantibodies may only be a universal characteristic of SMS 
in the absence of a paraneoplasia. 
Role of B Cells and GAD6a Autoantibodies in IDDM and 
SMS. In spontaneous rodent modds of IDDM, disease can 
be transferred by T cells but not B cells (10) and immuno- 
electronmicroscopic studies uggest hat fl cell destruction 
is mediated by cytotoxic T cells (40). The primary Th re- 
sponses to GAD6s in the nonobese diabetic mouse are of the 
Thl subset (12), which is consistent with induction of cyto- 
toxic T cell responses. Although autoantibodies to GAD6s 
have not been implicated as effectors of fl cell destruction, 
it is conceivable that B cells, expressing GAD6s-specific IgG 
on the surface, play an important role in antigen presenta- 
tion in IDDM. Activated B cells are particularly efficient 
presenters of low abundance antigens by virtue of antigen 
capture by their surface immunoglobulins (41) and may well 
be the principal antigen presenting cells that can maintain 
chronic autoimmunity o a rare antigen like GAD6s over the 
several years of progressive fl cell destruction. The antibody 
binding to an antigen can influence its processing inendosomal 
compartments, and consequently he presentation fepitopes 
to T cells. Thus, antibody binding can suppress ome epi- 
topes while boosting others (42). The identification of hu- 
moral autoimmune epitopes in the GAD6s molecule which 
are associated with either IDDM susceptibility (22) or pro- 
tection (36) may provide an example of how specificity of 
autoantibodies can influence autoimmune T cell responses 
resulting in either fl cell destruction and disease, or absence 
of disease. 
Do autoantibodies to GAD65 have a pathogenic role in 
SMS? Although the strong humoral autoimmune GAD6s 
responses in SMS may suggest amore direct role of autoanti- 
bodies in impairment of GABA-ergic neurons than in de- 
struction of fl cells, the pathogenicity ofSMS antibodies re- 
mains to be shown. It is noteworthy that in the absence of 
MHC class I expression (18) autoimmune effector mecha- 
nisms directed at neurons would be limited to antibody re- 
sponses. Furthermore, an involvement of a Th2 subset of 
CD4 § cells and strong antibody responses to GAD6s in the 
pathogenicity of SMS, in contrast to a requirement for a Thl 
subset and cytotoxic T cell responses for fl cell destruction, 
is consistent with the dichotomy of the two diseases. Thus 
SMS without IDDM would ensue in the absence of Thl helper 
cell and cytotoxic T cell responses to GAD6s. 
An autoantibody-mediated impairment of GABA-ergic 
neurons would, however, equire antigen exposure at the cell 
surface. Although there is some vidence to suggest that GAD 
can appear on the surface of neurons (43), the mechanisms 
of such exposure are unclear. GAD6s is believed to anchor 
at the cytosolic face of synaptic vesicle membranes and sur- 
face expression during exocytosis of GABA would require 
a membrane translocation step. The identification of am- 
phiphysin as a target of autoantibodies in a paraneoplastic 
SMS-like syndrome (39) does suggest that a localization of 
a protein to the cytosolic face of synaptic vesicle membranes 
can predispose it for autoantigenicity and that such proteins 
may reach the cell surface by an as yet unknown mechanism. 
Alternatively, SMS autoantibodies may not be involved in 
pathogenicity but rather be only a marker of disease. 
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